Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy
Authors:
- Alessandro RodolicoARAlessandro Rodolico
- Sofia Francesca AprileSASofia Francesca Aprile
- Pierfelice CutrufelliPCPierfelice Cutrufelli
- Sabrina CastellanoSabrina Castellano
- Carmen ConcertoCarmen Concerto
- Rosaria FurnariRFRosaria Furnari
- Claudia Savia GuerreraClaudia Savia Guerrera
- Ludovico MineoLMLudovico Mineo
- Giuseppe Alessio PlataniaGPGiuseppe Alessio Platania
- Antonino PetraliaAPAntonino Petralia
- Filippo CaraciFCFilippo Caraci
Open Access
- 20 September 2024
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (9) , 715-727
Abstract
Background Patients undergoing antipsychotic treatment for psychiatric disorders may experience challenges in functioning, either stemming from the severity of the illness or from the tolerability issues of prescribed medications. Objectives The aims of this cross-sectional study are to investigate the impact of adverse effects of antipsychotic drugs on patients’ daily life functioning, comparing oral and long-acting injectable (LAI) antipsychotics, and further dividing antipsychotics by receptor-binding profiles based on recently defined data-driven taxonomy. Methods This study involved patients with schizophrenia and bipolar spectrum disorders taking oral or LAI antipsychotics. Disability and functioning levels were assessed using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS), and the adverse effects of medications were evaluated using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and its subscales. Results The total sample consisted of 126 participants with a diagnosis of schizophrenia-spectrum or bipolar disorder, and included 54 males and 72 females ranging from 18 to 78 years of age (mean 45.1, standard deviation 14); 78 patients were taking oral antipsychotics and 48 were taking LAI antipsychotics, with subcategories of muscarinic (31), adrenergic/low dopamine (25), serotonergic/dopaminergic (23), dopaminergic (1), LAI muscarinic (15), LAI adrenergic (6), and LAI serotonergic/dopaminergic (25). The UKU total score for adverse effects showed significant correlations with WHODAS total score (ρ = 0.475; p < 0.001). Compared with oral antipsychotics, LAIs showed significantly lower scores in psychological (p = 0.014), autonomic (p = 0.008), other (p = 0.004), and sexual adverse effects (p = 0.008), as well as the UKU total score (p = 0.002). The Kruskal–Wallis test showed a significant difference in adverse effects between LAI and oral muscarinic subgroups, with LAIs having lower scores compared with antipsychotics binding to muscarinic receptors (p = 0.043). Conclusion These findings indicate clinically relevant differences in adverse effects among formulations, warranting further investigation for future observational studies.Keywords
This publication has 46 references indexed in Scilit:
- Data-Driven Taxonomy for Antipsychotic Medication: A New Classification SystemBiological Psychiatry, 2023
- Antipsychotic dose reduction compared to dose continuation for people with schizophreniaCochrane Database of Systematic Reviews, 2022
- Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophreniaCochrane Database of Systematic Reviews, 2022
- Antipsychotic maintenance treatment in schizophrenia and the importance of preventing relapseWorld Psychiatry, 2018
- The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical managementWorld Psychiatry, 2018
- What is a Psychiatric Disability?Health Care Analysis, 2013
- Mann‐Whitney U Test2010
- Effects of switching to long‐acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophreniaHuman Psychopharmacology: Clinical and Experimental, 2009
- Decreased density of muscarinic receptors in the superior temporal gyrusin schizophreniaJournal of Neuroscience Research, 2005
- Reduced expression of the muscarinic 1 receptor cortical subtype in schizophreniaAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2003